SEC Comment Letter 0000000000-23-003479 to SciMar Ltd. (CIK 0001952144)
SciMar Ltd. (CIK 0001952144)
Date: April 6, 2023 · CIK: 0001952144 · Accession: 0000000000-23-003479
AI Filing Summary & Sentiment
File numbers found in text: 024-12208
Letter
United States securities and exchange commission logo April 6, 2023 Mick Lautt Chief Executive Officer SciMar Ltd. 119 Main St., S. Dauphin, Manitoba. R7N 1K4 CANADA Re:SciMar Ltd. Offering Statement on Form 1-A Filed April 4, 2023 File No. 024-12208 Dear Mick Lautt: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nicholas Antaki
Show Raw Text
United States securities and exchange commission logo
April 6, 2023
Mick Lautt
Chief Executive Officer
SciMar Ltd.
119 Main St., S.
Dauphin, Manitoba. R7N 1K4 CANADA
Re:SciMar Ltd.
Offering Statement on Form 1-A
Filed April 4, 2023
File No. 024-12208
Dear Mick Lautt:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257
of Regulation A requires you to file periodic and current reports, including a Form 1-K which
will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nicholas Antaki